Pharmaceuticals, Biotechnology and Life Sciences
SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) — Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical…
JAKARTA, Indonesia and NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) — LeaderMed Group (LeaderMed), a global pharmaceutical development company, and…
Patient Special Access Program continues during Health Canada reviewMELBOURNE, Australia, Oct. 01, 2024 (GLOBE NEWSWIRE) — CLINUVEL has filed a…
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing…
Transaction supports further development of SER-155, following recent promising clinical data, and other cultivated live biotherapeutics, for multiple medically vulnerable…
BEVERLY, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) — Thrive Bioscience, Inc., a Boston-based manufacturer of instruments for advanced imaging, analytics,…
Formycon AG and its commercialization partner Fresenius Kabi jointly said Monday that the U.S. Food and Drug Administration (FDA) has approved FYB202/OtulfiTM1 (ustekinumab-aauz), a biosimilar to Stelara, for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis, the third Formycon biosimilar successfully approved by the FDA.
NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…
Renowned Biotech Leader to Contribute Expertise in Neuroscience and Therapeutics DevelopmentNEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) — Klotho Neurosciences,…
/ Not for distribution to U.S. news wire services or for dissemination in the United States / VANCOUVER, British Columbia,…